Recommendation for immune prophylaxis of respiratory syncytial virus infection in children
Uloženo v:
| Název: | Recommendation for immune prophylaxis of respiratory syncytial virus infection in children |
|---|---|
| Autoři: | Ping-Ing Lee, Yhu-Chering Huang, Chih-Jung Chen, Cheng-Hsun Chiu, Po-Yen Chen, Chun-Yi Lu, Ching-Chuan Liu, Nan-Chang Chiu, Hsin Chi, Chien-Yu Lin, Chun Yi Lee, Shuenn-Nan Chiu, Mei-Jy Jeng, Kuang-Che Kuo, Ren-Bin Tang, Yung-Feng Huang, Hui-Hsien Pan, Ming-Fang Cheng, Li-Min Huang, Ya-Li Hu, Tzou-Yien Lin |
| Zdroj: | Journal of Microbiology, Immunology and Infection, Vol 58, Iss 3, Pp 288-293 (2025) |
| Informace o vydavateli: | Elsevier BV, 2025. |
| Rok vydání: | 2025 |
| Témata: | monoclonal antibody, Prophylaxis, respiratory syncytial virus, palivizumab, nirsevimab, Microbiology, QR1-502 |
| Popis: | Respiratory syncytial virus (RSV) is the most common pathogen for young children hospitalized with bronchiolitis and pneumonia. Most infections occur below 1 year of age, and almost all children have been infected before 2 years of age. Monoclonal antibodies targeting RSV, such as palivizumab and nirsevimab, are accessible for preventing infection. A committee, consisting of experts in infectious diseases, cardiovascular diseases, and neonatal diseases in children, was assembled by the Pediatric Infectious Diseases Society of Taiwan. Collaborating with the Child Health Research Center at the National Health Research Institutes, Taiwan Pediatric Association, and Taiwan Society of Neonatology, the committee worked to formulate recommendations for immune prophylaxis against RSV infection in children. Palivizumab is recommended for the prevention of RSV infection in high-risk infants under 1 year old with one of the following (1) premature infants with a gestational age |
| Druh dokumentu: | Article |
| Jazyk: | English |
| ISSN: | 1684-1182 |
| DOI: | 10.1016/j.jmii.2025.02.007 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/40032543 https://doaj.org/article/3f5a52167ee1419daa148d1a344da883 |
| Rights: | CC BY NC ND |
| Přístupové číslo: | edsair.doi.dedup.....eced58c257c88eaa8fda33708eaf6ba6 |
| Databáze: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Respiratory syncytial virus (RSV) is the most common pathogen for young children hospitalized with bronchiolitis and pneumonia. Most infections occur below 1 year of age, and almost all children have been infected before 2 years of age. Monoclonal antibodies targeting RSV, such as palivizumab and nirsevimab, are accessible for preventing infection. A committee, consisting of experts in infectious diseases, cardiovascular diseases, and neonatal diseases in children, was assembled by the Pediatric Infectious Diseases Society of Taiwan. Collaborating with the Child Health Research Center at the National Health Research Institutes, Taiwan Pediatric Association, and Taiwan Society of Neonatology, the committee worked to formulate recommendations for immune prophylaxis against RSV infection in children. Palivizumab is recommended for the prevention of RSV infection in high-risk infants under 1 year old with one of the following (1) premature infants with a gestational age |
|---|---|
| ISSN: | 16841182 |
| DOI: | 10.1016/j.jmii.2025.02.007 |